Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Clinicaltrial registered12 Nov 2026

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

12 Nov 2026: Trial registered · Study of Multiple Ascending Doses (MAD) of M5542 in Participants With Moderate and Severe Eczema. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
12 Nov 2026
Title
Study of Multiple Ascending Doses (MAD) of M5542 in Participants With Moderate and Severe Eczema
Conditions
Eczema
Phase
Phase 1
Study Type
Interventional
Status
Not Yet Recruiting
Countries
Germany
Country
Germany
Reference
NCT07932795
Location
Germany
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from Germany

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.